Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Recruiting2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05947500Phase 2Active Not Recruiting

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT07215988Recruiting

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

NCT05269381Phase 1Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Showing all 3 trials

Research Network

Activity Timeline